Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 17;8(1):107-22.
doi: 10.3390/ph8010107.

A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer

Thomas G Frazier  1 , Kevin R Fox  2 , J Stanley Smith  3 , Christine Laronga  4 , Anita McSwain  5 , Devchand Paul  6 , Michael Schultz  7 , Joseph Stilwill  8 , Christine Teal  9 , Tracey Weisberg  10 , Judith F Vacchino  11 , Amy P Sing  11 , Dasha Cherepanov  12 , Wendy Hsiao  13 , Eunice Chang  14 , Michael S Broder  14
Affiliations

A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer

Thomas G Frazier et al. Pharmaceuticals (Basel). .

Abstract

To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multicenter chart review of ≥18 year old women with pN1mi breast cancer, HER2(-)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0-50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(-)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(-)/ER+ pN1mi breast cancer patients.

PubMed Disclaimer

References

    1. American Cancer Society Cancer Facts & Figures 2015. Atlanta: American Cancer Society. 2015. [(accessed on 23 February 2015)]. Available online: http://www.cancer.org/acs/groups/content/@editorial/documents/document/a....
    1. Maaskant A.J., van de Poll-Franse L.V., Voogd A.C., Coebergh J.W., Tutein Nolthenius-Puylaert M.C., Nieuwenhuijzen G.A. Stage migration due to introduction of the sentinel node procedure: A population-based study. Breast Cancer Res. Treat. 2009;113:173–179. - PubMed
    1. Van der Heiden-van der Loo M., Bezemer P.D., Hennipman A., Siesling S., van Diest P.J., Bongers V., Peeters P.H. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur. J. Surg. Oncol. 2006;32:710–714. - PubMed
    1. Salhab M., Patani N., Mokbel K. Sentinel lymph node micrometastasis in human breast cancer: An update. Surg. Oncol. 2011;20:e195–e206. - PubMed
    1. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 3. 2014. [(accessed on 16 October 2014)]. Available online: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

LinkOut - more resources